New leukaemia treatment outperforms standard chemotherapies
Researchers at The Australian National University (ANU) are working on a new treatment for an aggressive type of leukaemia that outperforms standard chemotherapies.
List view / Grid view
Researchers at The Australian National University (ANU) are working on a new treatment for an aggressive type of leukaemia that outperforms standard chemotherapies.
A cancer drug for patients with certain types of leukaemia and lymphoma can also prevent reactions to some of the most common airborne allergens, according to a recent Northwestern Medicine study. The promising data from this pilot study could have greater implications for adults with food allergies.
17 August 2016 | By Niamh Louise Marriott, Digital Content Producer
Cancerous acute lymphoblastic leukaemia cells produce and release special structures that can be traced in the blood, and therefore could have major implications on the diagnosis, monitoring, drug delivery and treatment of childhood leukaemia...
3 August 2016 | By Plasticell
Plasticell has signed a collaboration agreement with the National University of Ireland, Galway (NUI Galway) focused on methods of eradicating cancer stem cells...
28 July 2016 | By Caleb Radford, The Lead
Assessing a patient's levels of the P-glycoprotein soon after they start receiving Glivec therapy will help to predict that patient’s long-term response to the leukaemia drug, according to new research from SAHMRI and the University of Adelaide...
6 July 2016 | By Cold Spring Harbor Laboratory (CSHL)
Researchers have identified a new drug target in AML, created a candidate drug that hits the target and developed a new way of proving how the drug works...
28 June 2016 | By Victoria White, Digital Content Producer
Nordic Nanovector and AREVA Med have entered into a collaboration agreement to investigate the potential of a 212Pb-conjugated anti-CD37 antibodies...
In the pre-imatinib (Glivec®) era, two out of three patients died within five years from chronic myeloid leukemia and there was no hope for a curative treatment. Imatinib’s introduction in 2001 marked a breakthrough – as the first approved kinase inhibitor, it was a game-changer in cancer therapy and revolutionised…
10 June 2016 | By Victoria White, Digital Content Producer
Researchers have discovered a mutation in the ZBTB7A gene boosts the energy metabolism of acute myeloid leukaemia cells...
13 May 2016 | By Wojciech Czardybon, PhD, Project Manager, Discovery Laboratory Manager, Selvita S.A.
In this article, Wojciech Czardybon of Selvita discusses the potential of PIM/FLT3 dual inhibition in treating acute myeloid leukaemia and other cancers...
18 April 2016 | By Victoria White, Digital Content Producer
SEL24 is a dual inhibitor of PIM and FLT3 kinases. It is the first molecule with this mechanism of action to progress to such stage of development...
11 April 2016 | By Victoria White, Digital Content Producer
The collaboration aims to develop new antibody radionuclide conjugates (ARCs) optimised for the treatment of single cell leukaemias...
30 March 2016 | By Victoria White
Scientists from Cincinnati Children's Hospital Medical Centre have already used it to identify promising drug targets for acute myeloid leukaemia (AML)...
29 March 2016 | By Victoria White
The findings, made by scientists at the National University of Singapore, open a new door to treating the AML more effectively...
10 March 2016 | By Victoria White
Scientists are a step closer to creating blood stem cells that could reduce the need for bone marrow transplants in patients with cancer or blood disorders...